PHAS - PhaseBio Pharmaceuticals GAAP EPS of -$0.90 misses by $0.32 revenue of $0.58M misses by $1.39M
PhaseBio Pharmaceuticals press release (NASDAQ:PHAS): Q4 GAAP EPS of -$0.90 misses by $0.32. Revenue of $0.58M misses by $1.39M. Cash and cash equivalents at December 31, 2021, were $41.8 million, compared to $28.1 million at December 31, 2020. Shares -5.83% AH.
For further details see:
PhaseBio Pharmaceuticals GAAP EPS of -$0.90 misses by $0.32, revenue of $0.58M misses by $1.39M